Immune Response Monitoring for AAV Gene Therapies

This case study examines the immune responses associated with adenovirus-associated virus (AAV)-based vectors used for gene therapy. AAV vectors are commonly utilized for delivering genes to target tissues, potentially treating genetic diseases. Despite their general tolerability, there can be preexisting and treatment-induced immune responses against AAV capsids and transgene products, which may affect treatment outcomes. The study discusses the challenges in validating assays for these immune responses, particularly in gene therapy contexts. It notes that there are currently no universally accepted procedures for validating these assays, emphasizing the need for standardized methods in research settings to ensure reliable results. The document outlines key methodologies and recommendations for monitoring immune responses in AAV therapies, highlighting the importance of validating cellular responses to improve treatment efficacy. This case study aims to contribute to the body of knowledge surrounding AAV gene therapy and its immune implications.